CpG Type A Induction of an Early Protective Environment in Experimental Multiple Sclerosis

Figure 6

Clinical effect of adoptive transfer of pDCs from mice treated with CpG-A or PBS on EAE. (a) Mice received an i.v. injection of pDCs (5 × 10⁵ cells/mouse harvested from mice previously treated with CpG-A (Cp-GA-pDCs) or PBS (PBS-pDC)). Data represent average daily scores ± sem of two independent experiments; per group, ; Mann–Whitney test. Clinical parameters of disease scores following PBS-pDC or Cp-GA-pDCs treatment; (b) purity of pDC used for adoptive transfer. Numbers represent percentages of double positive cells. Data are representative of one of two independent experiments; (c) day of disease onset; (d) maximal score. Data represent mean ± sem from three independent experiments; . Mann–Whitney test; (e) IFN-β production from pDCs harvested from PBS or CpG-A-treated animals and cultured for 24 h in vitro. Supernatants were tested for the presence of IFN-β via ELISA. Data are mean ± sem from two independent experiments; per group. . Mann–Whitney test. (f) Ido1 mRNA transcripts levels, expression of mRNA being presented relative to respective control, namely, freshly harvested pDCs (in which fold change = 1; dotted line). . (g) Levels of IL-10 and IL-17 measured via ELISA following 72 h MOG (25 μg/ml) culture of isolated splenocytes. Data represent mean ± sem from three independent experiments, with mice per group; Mann–Whitney test.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)